



UNITED STATES PATENT AND TRADEMARK OFFICE

CL
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/812,797	03/30/2004	Choong-Chin Liew	4231/2055M	4501
29933	7590	09/27/2006	[REDACTED]	EXAMINER
PALMER & DODGE, LLP				SWITZER, JULIET CAROLINE
KATHLEEN M. WILLIAMS			[REDACTED]	[REDACTED]
111 HUNTINGTON AVENUE			ART UNIT	PAPER NUMBER
BOSTON, MA 02199				1634

DATE MAILED: 09/27/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/812,797	LIEW, CHOONG-CHIN	
	Examiner	Art Unit	
	Juliet C. Switzer	1634	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-48 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) _____ is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) 1-48 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-37, 42 and 52, drawn to methods for identifying markers for cancer and methods for diagnosis or prognosis of cancer, classified in class 435, subclass 6.
 - II. Claims 38-41 and 43-51 drawn to isolated nucleic acid molecules and kits comprising primers for isolating nucleic acid molecules, classified in class 536, subclass 23.1, for example.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case the products of invention II can be used in a variety of methods, including whole to determine gene expression not related to disease diagnosis or prognosis, nucleic acid purification methods, to express encoded polypeptides in vitro, and as hybridization probes for isolating related sequences in non-human organisms.

Further restriction requirement for groups I and II:

3. Groups I and II each encompass a multitude of different groups which are related to possible combinations of “one or more markers” from Table 3J, Table 3K and Table 3X . Table 3J, Table 3K and Table 3X contain the disclosure of hundreds of different putative markers.

Claims which require the detection of “one or more” of these markers include thousands of different possible groups which encompass all of the possible combinations of “one or more” markers selected from Table 3J, Table 3K and Table 3X . The claims read on a multitude of groupings of probes, each of which is separate and distinct one from another because they contain nucleic acid sequences that are structurally separate from one another. The search and examination of all possible groups would pose an enormous burden on the examiner and on the PTO search resources. In accordance with MPEP 803.04, if applicant elects **group I**, applicant should select a single combination of “one or more” markers from Table 3J, Table 3K and Table 3X for detection in the claimed methods. If applicant elects group II, applicant should elect a single combination of “two or more sequences from Table 3J, Table 3K and Table 3X ” for prosecution with group II (as required by claim 47). Further, from within that combination, applicant should select a single marker for prosecution in claims that require primers to only a single gene selected from Table 3J, Table 3K and Table 3X (for example claim 46).

The single elected combination will be examined, and if claims which recite and require the elected combination are found to be allowable, any combination which contains the elected combination will be rejoined prior to allowance. The rejoined subject matter will be allowed provided they are allowable in view of all patent statutes. For example, a claim may be free of the prior art but not compliant with 112 1st paragraph. Any claim which does not specifically refer to particular markers or combinations (for example, claim 1) will be treated as a “linking” claim relative to the claims which refer to particular markers, and the generic claims will be examined as generic claims.

Upon election of the single combination, applicant should identify the single combination by the names used in the claims and by any other identifiers used within the specification. Further, applicant should identify basis in the specification for the selected combination and where in Table 3J, Table 3K and Table 3X the entries related to the selected combination are found.

4. Furthermore, further restriction is required among the fourteen different types of cancer recited in the claims, for example in claim 19. Methods for identifying markers, staging or diagnosing and prognosing each of these different types of cancer is a related, but separate and distinct invention. For each different type of cancer a separate search of the prior art regarding the methods or products would be required, and each one would require a different consideration under 101 and 112 1st paragraph. The search and examination of all of these together would pose an enormous burden on the examiner. Any claim which does not specifically refer to particular markers or combinations (for example, claim 1) will be treated as a “linking” claim relative to the claims which refer to particular markers, and the generic claims will be examined as generic claims with respect to the different types of cancer. The further restriction will be applied only to the claims that specifically recite different types of cancer.

5. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as demonstrated by their different classification and recognized divergent subject matter and because inventions I-II require different searches that are not coextensive, examination of these claims would pose a serious burden on the examiner and therefore restriction for examination purposes as indicated is proper.

Art Unit: 1634

6. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier.** Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined.

See “Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b),” 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.**

Art Unit: 1634

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

7. A telephone restriction requirement was not made in this application due to an explicit request by Kathleen Williams stating a preference for not making elections in response to telephonic restriction requirements in the series of cases which includes this application.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Juliet C Switzer whose telephone number is (571) 272-0753. The examiner can normally be reached on Monday, Tuesday, or Thursday, from 9:00 AM until 4:30 PM.

Art Unit: 1634


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached by calling (571) 272-0735.

The fax phone numbers for the organization where this application or proceeding is assigned are (571) 273-8300. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571)272-0507.

Art Unit: 1634

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.



Juliet C. Switzer
Primary Examiner
Art Unit 1634

September 14, 2006